<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dinutuximab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dinutuximab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dinutuximab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="100730" href="/d/html/100730.html" rel="external">see "Dinutuximab: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="111693" href="/d/html/111693.html" rel="external">see "Dinutuximab: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F27386893"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Infusion reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious and potentially life-threatening infusion reactions occurred in 26% of patients treated with dinutuximab. Administer required prehydration and premedication, including antihistamines, prior to each dinutuximab infusion. Monitor patients closely for signs and symptoms of an infusion reaction during and for at least 4 hours following completion of each dinutuximab infusion. Immediately interrupt dinutuximab for severe infusion reactions and permanently discontinue dinutuximab for anaphylaxis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dinutuximab causes serious neurologic adverse reactions including severe neuropathic pain and peripheral neuropathy.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe neuropathic pain occurs in the majority of patients. Administer intravenous opioid prior to, during, and for 2 hours following completion of the dinutuximab infusion. In clinical studies of patients with high-risk neuroblastoma, grade 3 peripheral sensory neuropathy occurred in 2% to 9% of patients. In clinical studies of dinutuximab and related GD2-binding antibodies, severe motor neuropathy has occurred. Resolution of motor neuropathy did not occur in all cases. Discontinue dinutuximab for severe unresponsive pain, severe sensory neuropathy, and moderate to severe peripheral motor neuropathy.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F28807300"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Unituxin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F53275622"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Unituxin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F27387640"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-GD2;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F54809652"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">Not indicated for use in adults.</p></div>
<div class="block dop drugH1Div" id="F27640626"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="111693" href="/d/html/111693.html" rel="external">see "Dinutuximab: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Intravenous hydration and premedication with analgesics, antihistamines, and antipyretics are required prior to administration. Ensure adequate hematologic, respiratory, hepatic, and renal function prior to each cycle of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Dinutuximab may be associated with a moderate emetic potential based on adult sources; pediatric guidelines do not describe emetogenic potential guidance for dinutuximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>); antiemetics could be considered to prevent nausea and vomiting.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8334c4a0-f47a-47dd-a656-d00bc09cb559">Neuroblastoma, high-risk, post-consolidation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma, high-risk, post-consolidation:</b> Infants, Children, and Adolescents: IV: 17.5 mg/m<sup>2</sup>/day for 4 consecutive days for a maximum of 5 cycles. Infuse on days 4, 5, 6, and 7 during cycles 1, 3, and 5 (cycles 1, 3, and 5 are 24 days in duration); infuse on days 8, 9, 10, and 11 during cycles 2 and 4 (cycles 2 and 4 are 32 days in duration). Use in combination with sargramostim, aldesleukin, and isotretinoin. <b>Note: </b>Although the manufacturer's labeling includes aldesleukin (IL-2) as part of the original protocol, aldesleukin is no longer recommended for standard of care use with isotretinoin, dinutuximab, and sargramostim due to increased adverse effects and no additional efficacy benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35839426','lexi-content-ref-30442501']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35839426','lexi-content-ref-30442501'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6fc7672-3ba1-4f98-9c9e-f6cd53c46ea2">Neuroblastoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma, relapsed or refractory:</b> Limited data available: Infants, Children, and Adolescents: IV: 17.5 mg/m<sup>2</sup>/day for 4 consecutive days for up to 17 cycles. Infuse on days 2, 3, 4, and 5 of 21-day cycle; use in combination with temozolomide and irinotecan (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36206505','lexi-content-ref-32343642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36206505','lexi-content-ref-32343642'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Supportive therapy medications</b>
<b> for dinutuximab administration:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IV hydration: NS: IV: 10 mL/kg; infuse over 1 hour just prior to each dinutuximab infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Antihistamine: Diphenhydramine: IV: 0.5 to 1 mg/kg/dose; maximum dose: 50 mg/dose; administer over 10 to 15 minutes starting 20 minutes prior to dinutuximab infusion and every 4 to 6 hours as tolerated during the infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Antiemetics: Dinutuximab may be associated with a moderate emetic potential based on adult sources; pediatric guidelines do not describe emetogenic potential guidance for dinutuximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>); antiemetics could be considered to prevent nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:4em;">Antipyretics:</p>
<p style="text-indent:-2em;margin-left:6em;">Acetaminophen: Oral: 10 to 15 mg/kg/dose; maximum dose: 650 mg/dose; administer 20 minutes prior to each infusion and every 4 to 6 hours as needed for fever and pain.</p>
<p style="text-indent:-2em;margin-left:6em;">Ibuprofen: Oral: 10 mg/kg/dose; maximum dose: 400 mg/dose; every 6 hours as needed for control of persistent fever or pain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36434427','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36434427','lexi-content-ref-manu.1'])">Ref</a></span>); <b>Note:</b> Consider if platelet count is greater than 50 × 10<sup>3</sup>/mcL and no history of GI bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36434427']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36434427'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Analgesics: Morphine: IV: 50 <b>mcg</b>/kg; administer immediately prior to dinutuximab infusion initiation; continue as a morphine drip at a rate of 20 to 50 <b>mcg</b>/kg/hour during and for 2 hours following completion of dinutuximab infusion. May administer additional morphine doses of 25 to 50 <b>mcg</b>/kg IV as needed up to once every 2 hours followed by an increase in the drip rate in clinically stable patients. Consider conversion to fentanyl or hydromorphone if morphine is not tolerated; if pain is inadequately controlled with opioids, consider adjunct therapy with gabapentin or lidocaine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36434427','lexi-content-ref-35441791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36434427','lexi-content-ref-35441791'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Anaphylaxis, grade 3 or 4</i>: Permanently discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Capillary leak syndrome: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Moderate to severe, but not life-threatening: Immediately interrupt infusion; upon resolution, resume infusion at 50% of the previous rate.</p>
<p style="text-indent:-2em;margin-left:6em;">Life-threatening: Discontinue infusion for the current cycle; in subsequent cycles, infuse at 50% of the previous rate. If life-threatening capillary leak syndrome recurs, permanently discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hemolytic uremic syndrome:</i> Permanently discontinue therapy and administer supportive management.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hyponatremia, grade 4 (despite appropriate fluid management):</i> Permanently discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hypotension (symptomatic hypotension, systolic blood pressure [SBP] less than lower limit of normal for age, or SBP decreased by more than 15% compared to baseline):</i> Interrupt infusion; upon resolution, resume infusion at 50% of the previous rate. If blood pressure remains stable for ≥2 hours, gradually increase infusion rate as tolerated up to a maximum rate of 1.75 mg/m<sup>2</sup>/hour.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Infection (systemic)/sepsis, severe:</i> Discontinue therapy until infection resolves; may resume therapy with subsequent cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Infusion-related reaction:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate reaction (eg, transient rash, fever, rigors, and localized urticaria that respond promptly to symptomatic treatment): Reduce infusion rate by 50%; monitor closely. Upon resolution, gradually increase infusion rate up to a maximum of 1.75 mg/m<sup>2</sup>/hour.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe or prolonged reaction (eg, mild bronchospasm without other symptoms, angioedema that does not affect the airway): Immediately interrupt infusion; if symptoms resolve rapidly, resume infusion at 50% of the previous rate and monitor closely. If reaction recurs, discontinue therapy until the following day. If symptoms resolve and further treatment is warranted, premedicate with IV hydrocortisone 1 mg/kg (maximum dose: 50 mg/dose) and infuse at a rate of 0.875 mg/m<sup>2</sup>/hour in an intensive care unit. If reaction recurs again, permanently discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">Life-threatening reaction: Permanently discontinue therapy and administer supportive management.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neuropathy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Grade 4 sensory neuropathy or grade 3 sensory neuropathy that interferes with daily activities for more than 2 weeks: Permanently discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 2 or higher peripheral motor neuropathy: Permanently discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ocular neurological disorders (eg, blurred vision, photophobia, mydriasis, fixed or unequal pupils, optic nerve disorder, eyelid ptosis, and/or papilledema):</i> Discontinue infusion until symptom resolution; upon resolution, reduce <b>dose</b> by 50%. If reaction recurs, or if reaction is accompanied by visual impairment (eg, subtotal or total vision loss), permanently discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pain, severe (grade 3) unresponsive to maximum supportive measures:</i> Permanently discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Reversible posterior leukoencephalopathy syndrome: </i>Permanently discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Serum sickness, grade 3 or 4:</i> Permanently discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Transverse myelitis:</i> Permanently discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urinary retention (persistent after opioid discontinuation):</i> Permanently discontinue therapy.</p></div>
<div class="block dorp drugH1Div" id="F51109276"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney impairment</b>: Mild to severe: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). <b>Note:</b> Full dose dinutuximab dosing was administered to patients with neuroblastoma with end-stage kidney disease receiving dialysis (intermittent hemodialysis [n=1], peritoneal dialysis [n=1]); doses were well tolerated without added toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33381917']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33381917'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51109277"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F27736906"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in combination with granulocyte-macrophage colony stimulating factor, interleukin-2, and 13-cis-retinoic acid.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Capillary leak syndrome (40%), edema (17%), hypertension (14%), hypotension (60%), tachycardia (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria (37%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (18%), hypertriglyceridemia (16%), hypoalbuminemia (33%), hypocalcemia (27%), hypokalemia (43%), hypomagnesemia (12%), hyponatremia (58%), hypophosphatemia (20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite (15%), diarrhea (43%), vomiting (46%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (51%; grades 3/4: 34%), hemorrhage (17%; grades 3/4: 6%), lymphocytopenia (62%; grades 3/4: 51%), neutropenia (39%; grades 3/4: 34%), thrombocytopenia (66%; grades 3/4: 39%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (56%), increased serum aspartate aminotransferase (28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (21%; neutralizing antibodies: 52%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Bacteremia (grades 3/4: 13%), infection (device-related: 16%), sepsis (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Pain (85%), peripheral neuropathy (13%; grades 3/4: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hypoxia (24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (72%), infusion related reaction (60%; severe infusion related reaction: 26%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia (grades 3/4: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Peripheral motor neuropathy (grade 3: 1%), peripheral sensory neuropathy (9%; grade 3: 2% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic-uremic syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia, fixation of pupils, mydriasis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Neuralgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharoptosis, optic nerve damage, papilledema, photophobia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary retention (prolonged)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Reversible posterior leukoencephalopathy syndrome, transverse myelitis</p></div>
<div class="block coi drugH1Div" id="F27387643"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">History of anaphylaxis to dinutuximab.</p></div>
<div class="block war drugH1Div" id="F27640546"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Severe (grade 3 or 4) anemia, neutropenia, thrombocytopenia, and neutropenic fever were observed in dinutuximab-treated patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Capillary leak syndrome: Severe capillary leak syndrome was reported in close to one-fourth of patients receiving dinutuximab. Immediately interrupt infusion if capillary leak syndrome develops; infusion rate reduction and/or therapy discontinuation may be necessary. Initiate appropriate management in patients with symptomatic or severe capillary leak syndrome.</p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte abnormalities: Electrolyte abnormalities (such as hyponatremia, hypokalemia, and hypocalcemia) were reported in at least one-fourth of patients who received dinutuximab, including grade 3 or 4 events. In a study of a related anti-GD2 antibody, syndrome of inappropriate antidiuretic hormone secretion (SIADH) resulting in severe hyponatremia was reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemolytic uremic syndrome: Hemolytic uremic syndrome (without documented infection) resulted in renal insufficiency, electrolyte abnormalities, anemia, and hypertension in a small number of patients. Atypical hemolytic uremic syndrome recurred in one patient upon rechallenge. Permanently discontinue if hemolytic uremic syndrome develops; manage supportively.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: Severe hypotension occurred more frequently in patients receiving dinutuximab. Intravenous hydration is required prior to each infusion; closely monitor blood pressure during infusion. May require therapy interruption or discontinuation; initiate appropriate medical management in patients with a systolic blood pressure (SBP) less than lower limit of normal for age, or SBP that is decreased by more than 15% compared to baseline.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Severe (grade 3 or 4) bacteremia was reported more frequently in dinutuximab-treated patients, and required intravenous antibiotics or other urgent interventions. Sepsis was also observed in patients receiving dinutuximab. Monitor closely for signs/symptoms of systemic infection; may require therapy interruption until resolution of infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reaction: Serious and potentially life-threatening infusion reactions occurred in approximately one-fourth of patients treated with dinutuximab. Prehydration and premedications are required prior to each dinutuximab infusion. Monitor closely for infusion reaction. Immediately interrupt dinutuximab for severe infusion reactions and permanently discontinue dinutuximab for anaphylaxis. Infusion reactions typically occurred during infusion or within 24 hours of completion and may include facial and upper airway edema, dyspnea, bronchospasm, stridor, urticaria, and hypotension. Infusion reactions may require blood pressure support, bronchodilator therapy, corticosteroids, infusion rate interruption and/or reduction, or permanent therapy discontinuation. Infusion should be in a facility with cardiopulmonary medication/equipment available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: Dinutuximab causes serious neurologic adverse reactions including severe peripheral motor neuropathy and peripheral sensory neuropathy. In clinical studies of patients with high-risk neuroblastoma, grade 3 peripheral sensory neuropathy occurred in some patients. In clinical studies of dinutuximab and related GD2-binding antibodies, severe motor neuropathy has occurred. Resolution of motor neuropathy did not occur in all cases. Discontinue permanently for grade 2 or higher peripheral motor neuropathy, grade 3 sensory neuropathy that interferes with activities of daily living for more than 2 weeks, or grade 4 sensory neuropathy. In patients who experienced peripheral sensory neuropathy of any grade, the median duration was 9 days (range: 3 to 163 days).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular toxicity: Neurological ocular toxicity such as blurred vision, photophobia, mydriasis, fixed or unequal pupils, optic nerve disorder, eyelid ptosis, and papilledema were reported in clinical trials. In patients who experienced complete resolution of ocular toxicity, the median duration of toxicity was 4 days (range: 0 to 221 days). May require therapy interruption, dosage reduction, and/or treatment discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pain: Most patients experienced pain; severe pain was observed in over 50% of patients treated with dinutuximab; pain may occur despite analgesic/opioid therapy. Pain typically occurred during infusion and included abdominal, generalized, extremity, or back pain, neuralgia, musculoskeletal chest pain, and arthralgia. Premedication with analgesics, including opioids, is required prior to each dose, during the infusion, and for 2 hours following the infusion. Severe pain may require reduction of the infusion rate or therapy discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Reversible posterior leukoencephalopathy syndrome: Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported. Symptoms of RPLS include severe headache, hypertension, visual changes, seizures or lethargy. Begin appropriate management and discontinue dinutuximab in patients with RPLS signs/symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Transverse myelitis: Transverse myelitis has occurred in patients receiving dinutuximab; signs/symptoms (weakness, paresthesia, sensory loss or incontinence) should be evaluated promptly. Discontinue permanently in patients who develop transverse myelitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary retention: Prolonged urinary retention that persists for weeks to months after opioid discontinuation has occurred in patients receiving dinutuximab; discontinue permanently if urinary retention does not resolve following opioid discontinuation.</p></div>
<div class="block foc drugH1Div" id="F29032092"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Unituxin: 17.5 mg/5 mL (5 mL)</p></div>
<div class="block geq drugH1Div" id="F29032091"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F29835904"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Unituxin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">17.5 mg/5 mL (per mL): $4,159.55</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53275623"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Unituxin: 17.5 mg/5 mL (5 mL) [contains mouse (murine) and/or hamster protein]</p></div>
<div class="block admp drugH1Div" id="F52614586"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dinutuximab may be associated with a moderate emetic potential based on adult sources; pediatric guidelines do not describe emetogenic potential guidance for dinutuximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>); antiemetics could be considered to prevent nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Must be diluted prior to administration. Administer as an IV infusion only; do not administer as an IV push or bolus. Prior to each dinutuximab infusion, administer NS 10 mL/kg IV over 1 hour. Premedicate with analgesics, an antihistamine, and an antipyretic prior to administration. Infuse in an environment equipped to monitor for and manage infusion reactions. Interrupt infusion for toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">Initiate dinutuximab infusion at a rate of 0.875 mg/m<sup>2</sup>/hour for 30 minutes. Increase infusion rate gradually as tolerated to a maximum rate of 1.75 mg/m<sup>2</sup>/hour to infuse dose over 10 to 20 hours each day. Monitor patients closely for signs and symptoms of an infusion reaction during and for at least 4 hours following completion of each dinutuximab infusion.</p></div>
<div class="block use drugH1Div" id="F27387642"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Neuroblastoma:</b> Treatment of high-risk neuroblastoma (in combination with granulocyte-macrophage colony-stimulating factor [GM-CSF; sargramostim], interleukin-2 [IL-2; aldesleukin] and 13-cis-retinoic acid [RA; isotretinoin]) in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.</p></div>
<div class="block mst drugH1Div" id="F27640506"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Dinutuximab may be confused with daratumumab, denosumab, dostarlimab, durvalumab, isatuximab, loncastuximab tesirine, margetuximab, obinutuzumab, rituximab.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High-alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F27542720"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F27542717"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49298494"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who could become pregnant should use effective contraception during therapy and for 2 months after the last dose.</p></div>
<div class="block pri drugH1Div" id="F27640534"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Dinutuximab is a monoclonal antibody (IgG<sub>1</sub>). Potential placental transfer of human IgG is dependent upon the IgG subclass and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009). Based on the mechanism of action, dinutuximab may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F27640536"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if dinutuximab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">IgG molecules are excreted in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F27640664"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential (monitor closely during treatment), serum electrolytes (daily during treatment), renal function, blood pressure, oxygen saturation. Monitor for signs/symptoms of infusion reactions (during and for at least 4 hours after infusion), pain, peripheral neuropathy, capillary leak syndrome, infection/sepsis, hemolytic uremic syndrome, ocular toxicity, urinary retention, transverse myelitis, and/or reversible posterior leukoencephalopathy syndrome.</p></div>
<div class="block pha drugH1Div" id="F27640572"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Dinutuximab binds to the disialoganglioside GD2, which is highly expressed in neuroblastoma, most melanomas, and other tumors, as well as on normal tissues such as neurons, skin melanocytes, and peripheral sensory nerve fibers (Yu 2010). By binding to cell surface GD2, dinutuximab induces cell lysis (of GD2-expressing cells) through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).</p></div>
<div class="block phk drugH1Div" id="F27640614"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Pediatric patients (age: 3.9 ± 1.9 years): V<sub>dss</sub>: 5.4 L</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination, terminal: 10 days</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: Pediatric patients (age: 3.9 ± 1.9 years): 0.21 L/day; increased with body size</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F54492056"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Unituxin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Unituxin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Unituxin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33680926">
<a name="33680926"></a>Blom T, Lurvink R, Aleven L, et al. Treatment-related toxicities during anti-GD2 immunotherapy in high-risk neuroblastoma patients. <i>Front Oncol</i>. 2021;10:601076. doi:10.3389/fonc.2020.601076<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dinutuximab-drug-information/abstract-text/33680926/pubmed" id="33680926" target="_blank">33680926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36434427">
<a name="36434427"></a>Cabral J, Fernandez EI, Toy B, Secola R. Multidisciplinary clinical care in the management of patients receiving anti-GD2 immunotherapy for high-risk neuroblastoma. <i>Paediatr Drugs</i>. 2023;25(1):13-25. doi:10.1007/s40272-022-00544-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dinutuximab-drug-information/abstract-text/36434427/pubmed" id="36434427" target="_blank">36434427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35839426">
<a name="35839426"></a>Desai AV, Gilman AL, Ozkaynak MF, et al. Outcomes following GD2-directed postconsolidation therapy for neuroblastoma after cessation of random assignment on ANBL0032: a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2022;40(35):4107-4118. doi:10.1200/JCO.21.02478<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dinutuximab-drug-information/abstract-text/35839426/pubmed" id="35839426" target="_blank">35839426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33381917">
<a name="33381917"></a>Emberesh M, Rubinstein JD, Young J, Benoit SW, Dandoy CE, Weiss BD. Tolerance of dinutuximab therapy for treatment of high-risk neuroblastoma in two patients with end-stage renal disease on dialysis. <i>Pediatr Blood Cancer</i>. 2021;68(3):e28852. doi:10.1002/pbc.28852<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dinutuximab-drug-information/abstract-text/33381917/pubmed" id="33381917" target="_blank">33381917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35441791">
<a name="35441791"></a>Featherly J, Baxter Wojnowicz S, Steidl K, Burgess J. Lidocaine for dinutuximab-associated pain? A multicenter retrospective observational cohort study. <i>Pediatr Blood Cancer</i>. 2022;69(9):e29653. doi:10.1002/pbc.29653<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dinutuximab-drug-information/abstract-text/35441791/pubmed" id="35441791" target="_blank">35441791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30442501">
<a name="30442501"></a>Ladenstein R, Pötschger U, Valteau-Couanet D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. <i>Lancet Oncol</i>. 2018;19(12):1617-1629. doi:10.1016/S1470-2045(18)30578-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dinutuximab-drug-information/abstract-text/30442501/pubmed" id="30442501" target="_blank">30442501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36206505">
<a name="36206505"></a>Lerman BJ, Li Y, Carlowicz C, et al. Progression-free survival and patterns of response in patients with relapsed high-risk neuroblastoma treated with irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor. <i>J Clin Oncol</i>. 2023;41(3):508-516. doi:10.1200/JCO.22.01273<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dinutuximab-drug-information/abstract-text/36206505/pubmed" id="36206505" target="_blank">36206505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32343642">
<a name="32343642"></a>Mody R, Yu AL, Naranjo A, et al. Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2020;38(19):2160-2169. doi:10.1200/JCO.20.00203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dinutuximab-drug-information/abstract-text/32343642/pubmed" id="32343642" target="_blank">32343642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dinutuximab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi: 10.1002/pbc.27646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dinutuximab-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dinutuximab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference">
                  Unituxin (dinutuximab) [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20879881">
<a name="20879881"></a>Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. <i>N Engl J Med</i>. 2010;363(14):1324-1334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dinutuximab-drug-information/abstract-text/20879881/pubmed" id="20879881" target="_blank">20879881</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 100325 Version 173.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
